Profiel
Arturo Yudelevich was the founder of Andes Biotechnologies SA (founded in 2008) where he held the title of Director.
He is also the founder of Grupo Bios SA. Currently, Dr. Yudelevich holds the title of Professor at both Pontificia Universidad Católica de Chile and the University of Chile.
Dr. Yudelevich's education history includes an undergraduate degree from the University of Chile and a doctorate degree from Albert Einstein College of Medicine, Inc.
Actieve functies van Arturo Yudelevich
| Bedrijven | Functie | Begin |
|---|---|---|
| Grupo Bios SA | Founder | - |
| University of Chile | Corporate Officer/Principal | - |
| Pontificia Universidad Católica de Chile | Corporate Officer/Principal | - |
Eerdere bekende functies van Arturo Yudelevich
| Bedrijven | Functie | Einde |
|---|---|---|
Andes Biotechnologies SA
 Andes Biotechnologies SA BiotechnologyHealth Technology Andes Biotechnologies SA researches and develops effective treatments against cancer. It has developed a new proprietary technology based on the discovery of a novel family of RNA targets of mitochondrial origin that when disrupted by anti-sense technology they selectively destroy cancer cells. The company was founded by Luis O. Burzio, Arturo Yudelevich and Pablo D.T. Valenzuela in 2008 and is headquartered in Santiago, Chile. | Founder | - |
Opleiding van Arturo Yudelevich
| University of Chile | Undergraduate Degree |
| Albert Einstein College of Medicine, Inc. | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
| Grupo Bios SA | |
Andes Biotechnologies SA
Andes Biotechnologies SA BiotechnologyHealth Technology Andes Biotechnologies SA researches and develops effective treatments against cancer. It has developed a new proprietary technology based on the discovery of a novel family of RNA targets of mitochondrial origin that when disrupted by anti-sense technology they selectively destroy cancer cells. The company was founded by Luis O. Burzio, Arturo Yudelevich and Pablo D.T. Valenzuela in 2008 and is headquartered in Santiago, Chile. | Health Technology |
